Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Its Pancreatic Cancer Treatment
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...
Express News | VTv Therapeutics Inc - Net Loss Attributable to vTv Shareholders for Three Months Ended March 31, 2024, Was $4.9 Mln or $1.17 per Basic Share
Express News | VTv Therapeutics Q1 Operating Income USD -5.627 Million
Express News | VTv Therapeutics Q1 Operating Expenses USD 6.627 Million
vTv Therapeutics | 10-Q: Quarterly report
Express News | VTv Therapeutics Inc - Qtrly Revenue $1 Mln
Express News | VTv Therapeutics Inc - Qtrly Net Loss Attributable $1.17 per Basic Share
VTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
PDF Version HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy
VTv Therapeutics Files $250M Mixed Securities Shelf
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...
VTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees
Express News | VTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY
VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT
VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT
Press Release: VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update -- Recently completed $51 million PIPE from healthcare-focused institutional inve
VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
PDF Version Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adju
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. vTv Therapeutics (NASDAQ:VTVT) stock moved
VTv Therapeutics Enhances Investor Communication With Update
Express News | VTv Therapeutics Announces FDA Submission For Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes
VTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients With Type 1 Diabetes
PDF Version HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP3
No Data